Dong M. Shin, MD
Dr. Dong M. Shin is a board-certified medical oncologist and researcher at Emory University Hospital and the Winship Cancer Institute. He holds several titles, including the Frances Kelly Blomeyer Distinguished Endowed Chair in Cancer Research, Professor of Hematology and Medical Oncology, Professor of Otolaryngology, Professor of Biomedical Engineering, Director of the Head and Neck Cancer SPORE Program, and Georgia Cancer Coalition Distinguished Scholar at Winship Cancer Institute of Emory University.[1]
Dr. Shin has a national and international reputation as both a researcher and a clinician. He is recognized for his work in head and neck cancers as well as mesothelioma, thymoma, and thymic carcinoma.
Education and Career
Dr. Shin earned his medical degree at Yonsei University College of Medicine in Seoul, Korea. He completed an internship at Yonsei University Hospital and an internship and residency in Internal Medicine at Cook County Hospital in Chicago. Dr. Shin completed a fellowship in Medical Oncology at the University of Texas, M.D. Anderson Cancer Center in Houston.[1]
Following his medical education and training, Dr. Shin served as Professor of Oncology and Director of the Head and Neck Cancer Program at the University of Pittsburgh and as a faculty member in the Department of Head and Neck/Thoracic Medical Oncology at M.D. Anderson Cancer Center.[1]
Professional Memberships and Activities
Dr. Shin is actively involved in several professional medical societies and associations, including:[1]
- American Association of Cancer Research
- American College of Physicians (Fellow)
- American Head and Neck Society
- American Society of Clinical Oncology
- American Association of the Advancement of Science (Fellow)
Research
Dr. Shin’s research focuses on lung cancer, mesothelioma, and head and neck cancers. His work has explored establishing carcinogenesis models in preclinical and clinical settings, developing biomarkers in animal and human carcinogenesis, and developing molecular targeted prevention and therapies using epidermal growth factor receptor (EGFR) signaling pathways. He is also investigating new drug delivery to cancer patients using nanotechnology and tumor vaccine development.[2]
He has published over 380 scientific articles in journals such as The New England Journal of Medicine, Nature, The Journal of the National Cancer Institute, Cancer Research, Clinical Cancer Research, The Journal of Clinical Oncology, Nature Biotechnology, and many others. He has also served on the editorial boards of 20 scientific and oncology journals.[2]
His publications include:[2]
| A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma. Steuer CE Griffith CC Nannapaneni S Patel MR Liu Y Magliocca KR El-Deiry MW Cohen C Owonikoko TK Shin DM, Chen ZG Saba NF . Molecular cancer therapeutics 17 3 710716710-716 2018-03-01 PMC5935524 |
| A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment. Zhang H Yun S Batuwangala TD Steward M Holmes SD Pan L Tighiouart M Shin HJ Koenig L Park W Rycroft D Nannapaneni S Wang Y Chen ZG Shin DM, . International journal of cancer 131 4 956969956-69 2012-08-15 |
| A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. Wang X Li J Wang Y Koenig L Gjyrezi A Giannakakou P Shin EH Tighiouart M Chen ZG Nie S Shin DM. ACS nano 5 8 618461946184-94 2011-08-23 PMC3773705 |
| A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer. Bauman JE Chen Z Zhang C Ohr JP Ferris RL McGorisk GM Brandt S Srivatsa S Chen AY Steuer CE Shin DM, Saba NF Khuri FR Owonikoko TK. Cancers 14 11 2022-05-26 PMC9179856 |
| A network analysis of self-reported psychoneurological symptoms in patients with head and neck cancer undergoing intensity-modulated radiotherapy. Lin Y Bruner DW Paul S Miller AH Saba NF Higgins KA Shin DM, Zhang W Miaskowski C Xiao C. Cancer 128 20 373437433734-3743 2022-10-01 PMC9529994 |
